NCT03512405 2025-05-30Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaCity of Hope Medical CenterPhase 1/2 Active not recruiting36 enrolled
NCT03286114 2025-05-11Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With PembrolizumabUniversity of Michigan Rogel Cancer CenterPhase 1 Terminated16 enrolled 13 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled